Dermatitis News and Research

Latest Dermatitis News and Research

Wearable patch shows promise for treating children with peanut allergy

A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results from an ongoing clinical trial.

26 Oct 2016

New study finds no evidence of benefit from genetic disposition of eczema

Some genetic diseases persist for generation after generation because the genes that cause them can benefit human health.

6 Oct 2016

Study opens door towards personalized medicine for children with eczema

Atopic dermatitis, or eczema, is a common skin disorder that usually starts by 5 years of age, but virtually all of the studies that have defined the immune changes underlying eczema and are directing new treatment options have been done in adult skin.

5 Oct 2016

Skin phenotype of pediatric eczema opens door for personalized treatment of AD in infants

Researchers for the first time have identified the skin phenotype of pediatric eczema or atopic dermatitis (AD) in infants, opening the door for personalized treatment approaches for young children with eczema.

23 Sep 2016

Solution made of silver nanoparticles shows promise in healing diabetic foot ulcers

One of the major complications of diabetes is the appearance of wounds in the lower extremities that do not heal properly.

31 Aug 2016

MRSA correlated to eczema? An interview with Dr Bjorn Herpers

There is a lot of evidence that Staphylococcus aureus (S. aureus) is involved in eczema. Eczema is now thought to be caused by a barrier dysfunction of the skin that allows external triggers to cause an overshoot of inflammation.

31 Aug 2016

Cases of rotavirus infections fall by 84% thanks to vaccination

Figures published by Public Health England have shown that the number of diagnosed Rotavirus cases, a highly infectious virus which may cause vomiting and diarrhoea, have dropped by 84% since the introduction of a vaccine to the national childhood immunisation schedule in July 2013.

29 Aug 2016

Study finds oral immunotherapy safe, effective at suppressing peanut allergy in preschool children

Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found.

10 Aug 2016

Researchers develop new approach to manufacturing mechanical metamaterials

Ill-fitting joint sockets, contact dermatitis and sebaceous cysts are just a few of the problems plaguing prosthetic patients. They are all a result of the pressure that their prosthetic devices place on the soft tissue of their bodies.

29 Jul 2016

Eczema can increase patients' risk of developing several other health conditions

When a patient is diagnosed with eczema, the diagnosis of another medical condition may not be far behind.

28 Jul 2016

Study finds link between eczema and S. aureus bacteria

A new study published in the British Journal of Dermatology has shown that, on average, 70% of eczema patients are colonised with Staphylococcus aureus bacteria (S. aureus, including MRSA) on their skin lesions.

26 Jul 2016

Laundry pods more likely to cause poisoning injuries in small children than nonpod detergents

Laundry pod detergents are far more likely to cause poisoning injuries in young children than are nonpod laundry detergents, and are four times more likely to lead to hospitalization, according to findings published today from researchers at the University of Alabama at Birmingham.

28 Jun 2016

Early-life peanut consumption feasible and nutritionally safe for children, study finds

Introducing peanut-containing foods during infancy as a peanut allergy prevention strategy does not compromise the duration of breastfeeding or affect children's growth and nutritional intakes, new findings show.

13 Jun 2016

Subcutaneous treatment with cord blood stem cells improves eczema symptoms

A new study suggests that treatment with stem cells from umbilical cord blood might be an effective therapy for patients with moderate-to-severe eczema, or atopic dermatitis.

7 Jun 2016

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.

28 May 2016

Food-triggered atopic dermatitis in children may lead to life-threatening anaphylaxis risk

Elimination of the food that triggers atopic dermatitis, or eczema, is associated with increased risk of developing immediate reactions to that food, according to the results of a large-scale study recently published in the Journal of Allergy and Clinical Immunology.

24 May 2016

Domestic water hardness linked to eczema risk in children

High levels of water hardness in the home may be linked to the development of eczema early in life, according to a new study led by King's College London.

18 May 2016

Study shows canine AD shares significant features of human version

Atopic dermatitis (AD), a chronic inflammatory skin condition and the most common form of eczema, is estimated to afflict as much as 10 percent of the U.S. population, and is much more common now than it was 50 years ago. Veterinary clinical estimates also show that approximately 10 percent of dogs have atopic dermatitis.

26 Apr 2016

Researchers observe worrisome increase in anaphylaxis rate

Anaphylaxis, known to be a sudden and potentially life-threatening allergic reaction, seems to be increasing among children, according to a new study led by a team at the Research Institute of the McGill University Health Centre.

22 Apr 2016

Phase 3 study: Sarilumab monotherapy meets primary endpoint in active rheumatoid arthritis patients

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that a Phase 3 monotherapy study met its primary endpoint demonstrating that sarilumab was superior to adalimumab (marketed by AbbVie as HUMIRA) in improving signs and symptoms in patients with active rheumatoid arthritis (RA) at Week 24.

11 Mar 2016